your limit has been reached. plz Donate us to allow your ip full access, Email: sshnevis@outlook.com

Emetic risk of single, oral antineoplastic agents in adults*

Risk level	Agent
Moderate or high (≥30%)	Abemaciclib
	Avapritinib
	Bosutinib
	Cabozantinib
	Ceritinib
	Crizotinib
	Cyclophosphamide
	Enasidenib
	Fedratinib
	Hexamethylmelamine
	Imatinib
	Lenvatinib
	Lomustine
	Midostaurin
	Niraparib
	Procarbazine
	Ribociclib
	Rucaparib
	Selinexor
	TAS-102 (trifluridine-tipiracil)
	Temozolomide
	Vinorelbine
Minimal or low (<30%)	6-Thioguanine
	Acalabrutinib
	Afatinib
	Alectinib
	Alpelisib
	Axitinib
	Bexarotene
	Brigatinib
	Capecitabine
	Chlorambucil
	Cobimetinib
	Dabrafenib
	Dacomitinib
	Dasatinib
	Duvelisib
	Encorafenib
	Entrectinib
	Erdafitinib
	Erlotinib
	Estramustine
	Etoposide
	Everolimus
	Fludarabine

Risk level	Agent
Minimal or low (<30%) (continued)	Gefitinib
	Gilteritinib
	Glasdegib
	Hydroxyurea
	Ibrutinib
	Idelalisib
	Ivosidenib
	Ixazomib
	Lapatinib
	Larotrectinib
	Lenalidomide
	Lorlatinib
	Melphalan
	Methotrexate
	Neratinib
	Nilotinib
	Olaparib
	Osimertinib
	Palbociclib
	Panobinostat
	Pazopanib
	Pexidartinib
	Pomalidomide
	Ponatinib
	Regorafenib
	Ruxolitinib
	Sonidegib
	Sorafenib
	Sunitinib
	Talazoparib
	Tazemetostat
	Tegafur-Uracil
	Thalidomide
	Topotecan
	Trametinib
	Vandetanib
	Vemurafenib
	Venetoclax
	Vismodegib
	Vorinostat
	Zanubrutinib

* The classified emetic potential of oral agents is based on a full course of therapy and not a single dose.

Reproduced with permission from: Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: ASCO guideline update. J Clin Oncol 2020; 38:JCO2001296. Copyright © 2020 American Society of Clinical Oncology. All rights reserved.

Graphic 65923 Version 56.0